A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules

13 Mar 20264 min read0 viewsOBSERVATIONAL Trial

GIST

RECRUITING · OBSERVATIONAL · Pulmonary Nodule · Enrollment 100 · Sponsor: Vanderbilt-Ingram Cancer Center

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 13 Mar 2026. The item focuses on A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT06074133

Open Original Source More Feed Items

Related by Condition/Drug

Nat Rev OncRelated by Specialty

Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC

Oncology • 20 May 2026

Br J CancerRelated by Specialty

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

Oncology • 19 May 2026

Nat Rev OncRelated by Specialty

Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons

Oncology • 15 May 2026

JAMA OncRelated by Specialty

Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction

Oncology • 14 May 2026

NatureRelated by Specialty

Autonomous pathology research using agentic AI shows potential in oncology

Oncology • 05 May 2026

Br J CancerRelated by Specialty

CCNE1 Gain Defines a Therapy-Refractory Gastric Cancer Subtype

Oncology • 28 Apr 2026

Feed Metadata

Source

ClinicalTrials.gov